Our mission is to enable cancer patients to benefit from the advantages of an autologous blood transfusion. We potentially can contribute to an optimized outcome of oncological surgeries reducing the side effects accompanied with allogeneic blood transfusion by developing the medical device CATUVAB® to remove cancer cells from shed blood during surgery to enabling Autologous Blood Transfusion.
Meet our experienced Team
Lindis Blood Care was founded by Dr. Horst Lindhofer, developer of the first trifunctional antibody initially approved in Europe, Canada and Russia, and Dr. Franzpeter Bracht, former CEO/CBO of several Life Science companies.
1994 Recipient of the New Investigator Award at the 23rd ISEH Congress (International Society of Experimental Hematology), Minneapolis, USA for the development of a new manufacturing process of bispecific antibodies and first results in in vivo therapy
1992-1997 Research scientist at the GSF Institute for Immunology, together with the Munich University Hospital. During his tenure, Dr. Lindhofer was head of the clinical cooperation group “Bispecific Antibodies and Tumor Immunotherapy”. He started his academic work with the improvement of existing bispecific antibody approaches and laid the foundation for the development of the triomab® concept towards an innovative and modular platform technology
Dr. Lindhofer is the author of more than 50 publications, developer of numerous patents in the field of immunotherapy and has received several international awards
Ph.D. in Virology, Max-von-Pettenkofer Institute, Ludwig-Maximilians-Universität (LMU), Munich